Changes this week
Changes detected in the 7 days to Nov 21, 2026
- Minor: Brivekimig · Ulcerative Colitis Trial sites reduced: 69 → 61 locations
- Minor: VS-7375 · KRAS G12D-Mutated Colorectal Cancer Trial sites expanded: 32 → 35 locations
- Minor: Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA · Moderate to Severe Upper Facial Lines Trial sites expanded: 21 → 24 locations
- Minor: Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07) Trial sites reduced: 6 → 3 locations
- Minor: E6742 · Systemic Lupus Erythematosus Trial sites expanded: 54 → 63 locations
- Minor: Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis Trial sites expanded: 1 → 9 locations
- Minor: Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor · Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations Trial sites expanded: 127 → 131 locations
- Minor: Belantamab · Multiple Myeloma When Used as Monotherapy and in Combination Treatments Trial sites expanded: 44 → 59 locations
- Minor: Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and · PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study) Trial sites expanded: 46 → 49 locations
- Minor: Subcutaneous Injections of Elamipretide · Barth Syndrome Trial sites expanded: 0 → 7 locations
- Minor: Product Surveillance Registry Trial sites expanded: 401 → 404 locations
- Minor: Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure Trial sites expanded: 23 → 26 locations
- Minor: Tarlatamab · Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2 Trial sites reduced: 19 → 13 locations
- Minor: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments · a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) Trial sites reduced: 36 → 31 locations
- Minor: Ocrelizumab · Primary Progressive Multiple Sclerosis Study completion pushed from Jan 19, 2028 to Apr 15, 2028
- Minor: IPN10200 · Moderate to Severe Wrinkle-like Lines Between the Eyebrows Primary completion date changed from estimate of Dec 15, 2026 to Aug 12, 2026
- Minor: Dual Study Assessing Safety and Efficacy of Buntanetap · Early AD Final enrollment: 861 participants (planned 760)
- Minor: (Peak) A Phase 3 Randomized Trial of Bezuclastinib (CGT9486)+Sunitinib vs. Sunitinib · Gastrointestinal Stromal Tumors Interventions modified
- Minor: LIPUS-Brain · Early Alzheimer's Disease Study completion pushed from Jul 31, 2026 to Mar 31, 2027
- Minor: IPN10200 Over Time · Moderate to Severe Wrinkle-like Lines Between the Eyebrows Primary completion date changed from estimate of Dec 15, 2026 to Sep 28, 2026
- Minor: Telerehabilitation In The Home After Stroke Trial sites expanded: 27 → 32 locations
- Minor: HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor Trial arms changed: 9 → 10
- Minor: AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients Start date changed from estimate of Oct 2026 to Nov 1, 2026
- Minor: African Survey on Sepsis Knowledge (ASK) Trial sites expanded: 1 → 7 locations
- Minor: SHR-1139 in Healthy Volunteers Study completion pushed from Sep 30, 2026 to Jan 30, 2027
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates